CEO Greetings
Made by Nature, Healthcare Innovation by Dr. INVIVO

ROKIT Healthcare is committed to bringing the best healthcare solutions that come from a diversity of talent and convergence of fields.
No one is exempt from the problem of aging and age-related diseases, and the rhythm of regeneration and maximizing the potential of the human body is at the heart of what we do.

We want to provide the safest and effective organ regeneration platform services. I believe there is a paradigm shift in healthcare economics, and globally, there are needs in new therapeutic methods. Therefore, we would like to become a pioneer in this new paradigm of utilizing all advanced bio technologies such as organ regeneration, single cell RNA sequencing, tissue-engineering, bio inks and cell sheet, 4D bio fabrication, mRNA IPS technology and bio platform technology.

Since 4D bio fabricating technology is the best way to recapitulate the complex and functional human body, we have developed the therapeutic 4D bioprinter called Dr.INVIVO to use in tissue engineering and/or human organ regeneration. Dr.INVIVO is the world’s first sterile, all-in-one 4D organ regenerator. ROKIT’s autologous skin regeneration procedure using Dr.INVIVO has received regulatory approval for non-advanced therapy medicinal product (ATMP), meaning immediate access to the operating room (May 2019) by the European Medicines Agency (EMA) for the treatment of: 1) diabetic ulcer, 2) pressure ulcer, 3) scar revision, and 4) burn wound. During the clinical test, most of the patients with diabetic foot ulcer (DFU) showed significant reduction in wound size with distinct epithelization process for an average of 4 weeks after only one-time treatment of MA-ECM. In addition, the appropriate design of bio-inks and biomaterials can promise the effective customized 4D bioprinting system to regenerate human tissue and organs.

I am excited to share our core organ platforms. We will provide organ regeneration platforms where physicians can utilize our protocol, machine, material, and patient’s own cell. Please join us to open the new era of organ regeneration!

You, Seokhwan

Chairman/CEO